Tag
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and
The phase 2 ION224-CS2 trial demonstrates that ION224, a DGAT2 antisense oligonucleotide, safely improves liver histology in MASH patients independent of weight loss, offering a potential new therapeutic approach.
HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.
Dapagliflozin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis outcomes without increasing adverse events, according to a rigorous 48-week randomized trial.
Efimosfermin alfa, a long-acting FGF21 analogue, demonstrated a favorable safety profile and significant reductions in hepatic fat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase 2a randomized controlled
A phase 2b trial found that efruxifermin did not significantly improve fibrosis at 36 weeks in patients with compensated cirrhosis due to MASH, though longer-term benefit was suggested at 96 weeks.
